Adoption of Lutetium-177 PSMA radioligand therapy for metastatic castration resistant prostate cancer: a total population analysis in Germany from 2016 to 2020

被引：0
|
作者：
Luka Flegar
Smita George Thoduka
Damiano Librizzi
Markus Luster
Aristeidis Zacharis
Hendrik Heers
Nicole Eisenmenger
Hojjat Ahmadzadehfar
Matthias Eiber
Wolfgang Weber
Christer Groeben
Johannes Huber
机构：
[1] Philipps-University Marburg,Department of Urology
[2] Philipps-University Marburg,Department of Nuclear Medicine
[3] Reimbursement Institute,Department of Nuclear Medicine
[4] Klinikum Westfalen GmbH,Department of Nuclear Medicine
[5] Technische Universität Munich,undefined
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2023年 / 50卷
关键词：
Prostate cancer; mCRPC; Lutetium-; PSMA (; Lu-PSMA); Radioligand therapy; Health services research; Trends;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2188 / 2195
页数：7
相关论文
共 50 条
  • [41] Extended radioligand therapy with Lu-177-PSMA-617 in patients with advanced metastatic castration-resistant prostate cancer
    Mader, N.
    Baumgarten, J.
    Groener, D.
    Ngoc, C. Nguyen
    Davis, K.
    Banek, S.
    Tselis, N.
    Happel, C.
    Gruenwald, F.
    Sabet, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S489 - S489
  • [42] Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial
    Ardolino, Luke C.
    Dear, Rachel
    Armstrong, Andrew J.
    Gillessen, Silke
    Joshua, Anthony M.
    EUROPEAN UROLOGY, 2023, 84 (04) : E94 - E95
  • [43] Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial
    Morris, Michael J.
    Sartor, Oliver
    de Bono, Johann S.
    Fizazi, Karim
    Tagawa, Scott T.
    EUROPEAN UROLOGY, 2023, 84 (01) : 7 - 8
  • [44] Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with 177Lu-PSMA radioligand therapy
    von Eyben, Finn Edler
    Kulkarni, Harshad R.
    Baum, Richard P.
    THERANOSTICS, 2020, 10 (11): : 4900 - 4902
  • [45] PSMA radioligand therapy rechallenging: expanding the therapeutic possibilities in metastatic castration resistant prostate cancer
    Volpe, Fabio
    Piscopo, Leandra
    Klain, Michele
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 (13) : 4163 - 4164
  • [46] 177Lu -PSMA-I&T PSMA radioligand therapy in metastatic castration - resistant prostate cancer: First clinical trial in Asia
    Bu, Ting
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2019, 62 : S527 - S528
  • [47] Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Rapid Recommendation
    Garje, Rohan
    Rumble, R. Bryan
    Parikh, Rahul A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (31) : 3664 - +
  • [48] 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration Resistant Prostate Cancer: Safety, Efficacy and Quality of Life Assessment
    Yadav, M. P.
    Bal, C.
    Ballal, S.
    Tripathi, M.
    Damle, N. A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S646 - S646
  • [49] Therapeutic response and safety of radioligand therapy with 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer patients
    Ashfaq, Wardah
    Rehman, Khurram
    Shahid, Abubaker
    Younis, Muhammad Numair
    MEDICAL ONCOLOGY, 2024, 41 (09)
  • [50] 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with a Single Functioning Kidney
    Zhang, Jingjing
    Kulkarni, Harshad R.
    Singh, Aviral
    Schuchardt, Christiane
    Niepsch, Karin
    Langbein, Thomas
    Baum, Richard P.
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (11) : 1579 - 1586
12345